Vitamin K antagonist therapy was regarded as unsuitable for 1195 individuals because the risk of stroke was only moderate, as assessed by a score of just one 1 on the CHADS2 scale. There have been 2092 patients who did not want to take supplement K antagonists; in the case of 815 patients , this is the only real reason that vitamin K antagonist therapy was unsuitable. Early Termination of Study The data and safety monitoring committee examined the results of the first planned interim analysis of efficacy on February 19, 2010, at which time 104 events had occurred, and observed a treatment benefit and only apixaban for the principal outcome that exceeded 4 SD.An investigator from the Lovelace Respiratory Analysis Institute in Albuquerque also participated in this study. An abstract of the paper is normally available at the journal’s Site. View abstract.. Werner Wenning, M.D., Aiden Haghikia, M.D.D., David B. Clifford, M.D., Peter F. Behrens, M.D., Andrew Chan, M.D., and Ralf Gold, M.D.S. As of 2008 June, a lot more than 40,000 patients had received natalizumab during participation in medical research or during open-label use; approximately 14,000 had taken the medication for at least 12 weeks, and 6600 for at least 1 .gov amount, NCT00030966]), in which natalizumab was found in mixture with interferon beta-1a , and one in an individual with Crohn’s disease who had received prior immunosuppressive therapy.